Tuberous sclerosis shows Alzheimer’s-like tau marker levels due to chronic mTOR activation
Duke University researchers on 11 September compared plasma p‑tau217 in 63 people with tuberous sclerosis, 25 with Alzheimer’s disease, and 116 cognitively healthy controls. The marker was significantly higher than in healthy peers, began rising at a younger age, and was statistically indistinguishable from the Alzheimer’s group.
Tuberous sclerosis is a rare inherited disorder affecting 7–12 per 100,000 individuals, caused by loss‑of‑function mutations in TSC1 or TSC2, which normally restrain mTOR. Without this brake, mTOR remains hyperactive throughout life, leading to benign tumors in brain, kidneys, heart and skin, and epilepsy in most patients.
Earlier Duke work found neuronal damage markers in cerebrospinal fluid and post‑mortem tau aggregates resembling Alzheimer’s pathology but lacking amyloid plaques. The link lies in chronic mTOR activation blocking autophagy, damaging synapses and allowing tau to accumulate — processes mirroring Alzheimer’s neurodegeneration.
The study shifted to blood using p‑tau217, the most accurate early tau marker available. After adjusting for age and sex, p‑tau217 remained significantly higher than healthy (p < 0.0001 vs healthy; p = 0.071 vs AD) and kidney contribution was noted as modest. Independent age‑sex matching confirmed the same result.
mTOR is the same pathway targeted by rapamycin longevity hypotheses; rapamycin extended lifespan in worms, yeast, flies and, in 2009, in normal mice. Human longevity trials have been inconclusive, but tuberous sclerosis offers a natural model of lifelong mTOR hyperactivity producing Alzheimer’s‑level tau pathology. Authors plan to test whether rising p‑tau217 predicts memory decline. Clinically, Aeovian is testing the selective mTORC1 inhibitor AV078 for epilepsy in this disease; if mTOR drives tau pathology, AV078 could also treat early Alzheimer‑like tau changes.
🔗 Read original →